Anticoagulation in Cancer Patients

Cancer Types and Anticoagulation

The National Comprehensive Cancer Network recommends that patients with gastrointestinal and genitourinary malignancies, especially those with intact intraluminal tumors, avoid Direct Oral Anticoagulants (DOACs) due to significantly increased bleeding risk 1, 2
Patients with gastrointestinal (GI) malignancies have significantly higher bleeding rates with DOACs compared to low-molecular-weight heparins (LMWH) 1, 2
Subgroup analyses from the Hokusai VTE-Cancer trial showed that patients with GI cancer had a 13.2% bleeding rate with edoxaban versus 2.4% with dalteparin (p=0.0224) 1
The American Society of Clinical Oncology suggests that patients with unoperated GI malignancies, residual GI tumors, or active mucosal tumors in the GI tract should avoid DOACs 3, 4, 5
Patients with genitourinary (GU) malignancies also show increased bleeding risk with DOACs, particularly those with unoperated or residual GU malignancies 1, 2, 3, 4, 5
The National Comprehensive Cancer Network guidelines state that DOACs should be avoided in patients with central nervous system (CNS) malignancies, particularly those with intracranial or CNS bleeding within the past 4 weeks, treated brain metastases, or other CNS malignancies 4, 5
Hematological malignancies increase the risk of bleeding with anticoagulation, and patients with persistent thrombocytopenia (<50,000/mL) should avoid DOACs 3, 4, 5

Active major bleeding in critical sites (intracranial, pericardial, retroperitoneal, intraocular, intra-articular, intraspinal) is an absolute contraindication for DOACs 4
Severe, uncontrolled malignant hypertension, severe coagulopathy (e.g., liver failure), and concurrent use of potent P-glycoprotein or CYP3A4 inhibitors or inducers are also absolute contraindications for DOACs 4
Severe renal dysfunction (creatinine clearance <15 mL/min) is a contraindication for DOACs 3

Low-molecular-weight heparins (LMWH) are preferred for cancer patients with high bleeding risk, as they represent a short-term anticoagulation option in patients not suitable for DOACs 3, 4, 5
Vitamin K antagonists (VKAs) are indicated in patients with moderate-severe mitral stenosis or mechanical prosthetic valves 3
Antiplatelet therapy is not recommended for stroke or systemic thromboembolism prevention in cancer patients with atrial fibrillation 3

Assess cancer type and location, and avoid DOACs in patients with GI or GU cancer with intact tumors, CNS malignancy, or recent CNS bleeding 1, 2, 3, 4, 5
Evaluate bleeding risk factors, including platelet count, renal function, and potential drug interactions 3, 4, 5
Consider alternative anticoagulation options, such as LMWH or VKAs, based on patient-specific factors 3, 4, 5
Monitor patients closely, with regular assessment of bleeding risk and reassessment of anticoagulation strategy if cancer status changes 3, 4, 5

Patients who prefer oral administration over subcutaneous injections may be preferred for DOACs over LMWH 6
Patients taking medications with significant drug-drug interactions with DOACs should prefer LMWH over DOACs, as outlined by the European Society for Medical Oncology 7
Overlooking potential drug-drug interactions between DOACs and anticancer agents, especially with tyrosine kinase inhibitors and immune-modulating agents, can lead to adverse effects, according to the American Society of Clinical Oncology 7
Not accounting for chemotherapy-induced nausea and vomiting which may affect DOAC absorption is crucial in patient management, as recommended by the National Comprehensive Cancer Network 7